Silence Therapeutics reports Q1 EPS (20c), consensus (41c)

Reports Q1 revenue $142,000, consensus $3.58M. “Silence delivered another strong quarter focused on clinical and operational execution,” said Craig Tooman, President and Chief Executive Officer at Silence. “We remain focused on advancing enrollment into the SANRECO Phase 2 study of divesiran, a first-in-class siRNA program in PV, and continue to be on-track to complete enrollment by the end of this year. We are also looking forward to sharing additional results from the Phase 1 portion of the SANRECO study during an oral presentation at EHA next month.”